With this renewal application to the NIMHD Endowment Program for Increasing Research and Institutional Resources Capacity (S21), Charles R. Drew University of Medicine and Science (CDU) proposes to continue building capacity and infrastructure that facilitate and enhance the university's ongoing career development and research activities in the arena of health disparities. Through the NIMHD-endowed Life Sciences Institute (LSI) (formerly Medical Sciences Institute [MSI]), and related federally funded research activities, the CDU leadership and faculty are rigorously and creatively designing and developing a research environment in which a strong, diverse scientific community can productively collaborate in addressing solutions to the complex problem of health disparities. The mission of the 5-Year Endowment Strategic Plan is to guide the university in its allocation of endowment funds to support activities that maximize the university?s efforts to substantially improve the health status of underserved communities through supporting biomedical and behavioral research and its translation into high-quality clinical outcomes, improved community health, and progressive health policy. The proposed renewal will vitally bolster the LSI endowment portfolio currently managed through a collaboration with the University of California, Los Angeles (UCLA) Endowment Foundation, further strengthening the established operations base of effective and sophisticated portfolio management consistent with the highest national standards of fiduciary oversight. The endowment portfolio will be allocated among a number of asset classes that flexibly include domestic equity, domestic fixed income, international equity, international fixed income, private equity, venture capital, and cash to ensure the proper level of diversification and the fiscal solvency necessary for creating an empowering and self-sustaining research infrastructure at CDU. The overall programmatic objective of this proposal is to enhance the recruitment and retention of individuals currently underrepresented in the biomedical, clinical, behavioral, and social sciences and community health science through achievement of three specific aims: (1) establish a Minority Health and Health Disparities Research Faculty Retention Fund, as a means of successfully transitioning junior faculty from career development grant support to independent investigator-initiated research grant support;(2) recruit, retain, and support ?community faculty? within the Division of Community Engagement, a novel academic track designed to create a transformational learning environment at CDU and a model of Community-Academic partnership immersion for the nation;and (3) continue effective management of the endowment portfolio at a level consistent with the highest fiduciary standards in the nation.

Public Health Relevance

Endowment funding is sought to continue building capacity and support infrastructure for the university?s ongoing health disparities research activities; specifically in the areas of career development for junior faculty; community engagement for successful community research; and effective management of the endowment portfolio.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Research and Institutional Resources Health Disparities Endowment Grants -Capacity Building (S21)
Project #
3S21MD000103-14S1
Application #
8933610
Study Section
Special Emphasis Panel (ZMD1-RN (04))
Program Officer
Stinson, Nathaniel
Project Start
2001-09-30
Project End
2016-08-31
Budget Start
2014-09-26
Budget End
2015-08-31
Support Year
14
Fiscal Year
2014
Total Cost
$250,000
Indirect Cost
Name
Charles R. Drew University of Medicine & Science
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Chung, Seyung S; Dutta, Pranabananda; Austin, David et al. (2018) Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget 9:32943-32957
Singh, Rajan; Pervin, Shehla; Lee, Se-Jin et al. (2018) Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases. Diabetes Metab Syndr Obes 11:65-84
Jenders, Robert A; Adlassnig, Klaus-Peter; Fehre, Karsten et al. (2018) Evolution of the Arden Syntax: Key Technical Issues from the Standards Development Organization Perspective. Artif Intell Med 92:10-14
Hanuscin, Chris; Zahmatkesh, Golara; Shirazi, Anaheed et al. (2018) Socio-Demographic and Mental Health Profile of Admitted Cases of Self-Inflicted Harm in the US Population. Int J Environ Res Public Health 15:
Elsaid, Ahmed F; Shaheen, Magda; Ghoneum, Mamdooh (2018) Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial. Exp Ther Med 15:2313-2320
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
Kermah, Dulcie; Shaheen, Magda; Pan, Deyu et al. (2017) Association between secondhand smoke and obesity and glucose abnormalities: data from the National Health and Nutrition Examination Survey (NHANES 1999-2010). BMJ Open Diabetes Res Care 5:e000324
Yen, Eric Y; Shaheen, Magda; Woo, Jennifer M P et al. (2017) 46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013: A Nationwide Population-Based Study. Ann Intern Med 167:777-785
Pervin, Shehla; Singh, Vineeta; Tucker, Alexandria et al. (2017) Modulation of transforming growth factor-?/follistatin signaling and white adipose browning: therapeutic implications for obesity related disorders. Horm Mol Biol Clin Investig 31:
Wang, Piwen; Solorzano, Walter; Diaz, Tanya et al. (2017) Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp 13:1-11

Showing the most recent 10 out of 85 publications